Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity.
Animals
Apoptosis
Cell Proliferation
Colonic Neoplasms
/ immunology
Female
Granulocyte-Macrophage Colony-Stimulating Factor
/ administration & dosage
Humans
Immunomodulation
Immunotherapy
/ methods
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Newcastle disease virus
/ genetics
Oncolytic Virotherapy
/ instrumentation
Tumor Cells, Cultured
Tumor Microenvironment
Xenograft Model Antitumor Assays
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
20
10
2020
revised:
05
02
2021
accepted:
04
06
2021
pubmed:
6
7
2021
medline:
11
2
2022
entrez:
5
7
2021
Statut:
ppublish
Résumé
A recombinant Newcastle Disease Virus (NDV), encoding either a human (NDVhuGM-CSF, MEDI5395) or murine (NDVmuGM-CSF) GM-CSF transgene, combined broad oncolytic activity with the ability to significantly modulate genes related to immune functionality in human tumor cells. Replication in murine tumor lines was significantly diminished relative to human tumor cells. Nonetheless, intratumoral injection of NDVmuGM-CSF conferred antitumor effects in three syngeneic models
Identifiants
pubmed: 34224361
pii: 1535-7163.MCT-20-0902
doi: 10.1158/1535-7163.MCT-20-0902
pmc: PMC9398146
doi:
Substances chimiques
Granulocyte-Macrophage Colony-Stimulating Factor
83869-56-1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1723-1734Informations de copyright
©2021 The Authors; Published by the American Association for Cancer Research.
Références
Cancer Immunol Res. 2014 Dec;2(12):1125-31
pubmed: 25480554
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Front Immunol. 2017 Apr 06;8:391
pubmed: 28428785
Nat Rev Immunol. 2006 Nov;6(11):836-48
pubmed: 17063185
Oncotarget. 2017 Jan 3;8(1):1213-1225
pubmed: 27901484
Clin Exp Med. 2012 Jun;12(2):97-103
pubmed: 21688119
Sci Transl Med. 2014 Mar 5;6(226):226ra32
pubmed: 24598590
Immunity. 2014 Nov 20;41(5):830-42
pubmed: 25517615
J Virol. 2016 May 12;90(11):5343-5352
pubmed: 27009956
Nature. 2015 Apr 16;520(7547):373-7
pubmed: 25754329
Immunity. 2013 Jul 25;39(1):27-37
pubmed: 23890061
Nat Rev Drug Discov. 2015 Sep;14(9):642-62
pubmed: 26323545
Nat Rev Drug Discov. 2019 Sep;18(9):689-706
pubmed: 31292532
Sci Transl Med. 2015 Apr 15;7(283):283ra52
pubmed: 25877890
Future Microbiol. 2012 Mar;7(3):347-67
pubmed: 22393889
Eur J Surg Oncol. 2015 Apr;41(4):450-6
pubmed: 25682184
Mol Ther. 2017 Aug 2;25(8):1917-1932
pubmed: 28578991
N Engl J Med. 2016 Feb 4;374(5):493-4
pubmed: 26840144
Clin Cancer Res. 2017 Jul 1;23(13):3416-3427
pubmed: 28069723
Mol Cancer Ther. 2018 May;17(5):1024-1038
pubmed: 29545330
Proc Natl Acad Sci U S A. 1989 Feb;86(4):1213-7
pubmed: 2645577
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
J Virol. 2012 Mar;86(6):2900-10
pubmed: 22258243
Sci Transl Med. 2018 Jan 3;10(422):
pubmed: 29298865
Int J Oncol. 2012 Mar;40(3):840-50
pubmed: 22102168
JCI Insight. 2019 Mar 21;4(6):
pubmed: 30895946
Adv Virol. 2012;2012:186512
pubmed: 22312362
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
Cancer Immunol Immunother. 2020 Jun;69(6):1015-1027
pubmed: 32088771
Nat Rev Drug Discov. 2018 Jul;17(7):509-527
pubmed: 29904196
EBioMedicine. 2016 Jul;9:31-36
pubmed: 27407036
Curr Cancer Drug Targets. 2007 Mar;7(2):157-67
pubmed: 17346107
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9730-5
pubmed: 8790399
Cancer Immunol Res. 2017 Jan;5(1):29-41
pubmed: 27923825
J Clin Invest. 2018 Nov 1;128(11):5184
pubmed: 30277478